Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year Low – Time to Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s stock price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $8.91 and last traded at $10.40, with a volume of 592113 shares trading hands. The stock had previously closed at $9.37.

Analyst Ratings Changes

A number of research firms have recently issued reports on BCAX. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday, March 13th. Finally, HC Wainwright decreased their price target on shares of Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating for the company in a research report on Monday. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $36.50.

Bicara Therapeutics Stock Up 11.0 %

The stock’s fifty day moving average price is $12.84 and its 200 day moving average price is $17.03.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08). On average, equities research analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Red Tree Management LLC bought a new stake in Bicara Therapeutics during the 4th quarter valued at about $55,230,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Bicara Therapeutics by 171.9% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock valued at $37,893,000 after acquiring an additional 1,375,265 shares during the last quarter. Deep Track Capital LP boosted its holdings in shares of Bicara Therapeutics by 151.0% during the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company’s stock valued at $34,840,000 after acquiring an additional 1,203,148 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Bicara Therapeutics by 1,457.9% during the 4th quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company’s stock valued at $18,997,000 after acquiring an additional 1,020,528 shares during the last quarter. Finally, Foresite Capital Management VI LLC purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at about $16,549,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.